Biogen Inc. BIIB NASDAQ

Biogen Inc. (BIIB) generated $512M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $43.9M, free cash flow was $555.9M.

Free cash flow margin was 24.4% of revenue. Cash conversion ratio was -10.47x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (83/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (65/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (55/100) — Cash conversion ratio was -10.47x suggests some earnings are non-cash items

Overall SharesGrow Score: 60/100 with 2/7 criteria passed.